Cost-utility analysis of dapagliflozin compared to sulfonylureas for type 2 diabetes as second-line treatment in indian healthcare payer’s perspective

Cost-utility analysis of dapagliflozin compared to sulfonylureas for type 2 diabetes as second-line treatment in indian healthcare payer’s perspective

Background: Type 2 diabetes mellitus (T2DM) is a leading health issue, causing economic burden in India. Pharmacotherapy is a major cost driver in diabetic care usually funded through out of pocket expenditure; however, there has been a very limited economic evaluation evidence to guide the choice o...

Full description

Saved in:
Bibliographic Details
Main Authors: Bhavani Shankara Bagepally, Usa Chaikledkaew, Sitaporn Youngkong, Thunyarat Anothaisintawee, Montarat Thavorncharoensap, Charungthai Dejthevaporn, Ammarin Thakkinstian
Other Authors: Indian Council of Medical Research
Format: Article
Published: 2022
Subjects:
Economics, Econometrics and Finance
Medicine
Online Access:https://repository.li.mahidol.ac.th/handle/123456789/76881
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Mahidol University

Internet

https://repository.li.mahidol.ac.th/handle/123456789/76881

Similar Items